Medical Research Finder

Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

© 2026 meRfi®

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

AuthorsReferences (Sources)

meRfi® AI Chat

Non-Small-Cell Lung Cancer (NSCLC) & Mutated variants (“drivers”)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Register for a free trial

Navigation

Contents

The identification of various oncogenic driver mutations in individuals with non-small cell lung cancer (NSCLC) has paved the way for the creation of personalized therapies. These treatments are tailored to target specific molecular changes, especially within the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) gene.
Solassol et al. 2019 Biomolecules 9(11): 668

see also:
Cancer / Tumors & Personalized Medicine / Precision Medicine

…

References (Sources)

FDA- and EMA-Approved Tyrosine Kinase Inhibitors in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Safety, Tolerability, Plasma Concentration Monitoring, and Management
Solassol et al. 2019 Biomolecules 9(11): 668
Review
Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/ International Association for the Study of Lung Cancer/ Association for Molecular Pathology Clinical Practice Guideline Update
Kalemkerian et al. 2018
Novel molecular targets for the treatment of lung cancer
Rosell et al. 2020 Current Opinion in Oncology. 32(1): 37-43
Sequencing therapies in oncogene-driven non-small-cell lung cancer: how to get the best mileage?
Sukrithan et al. 2019 Future Oncology 15: 2899–2904
The emerging development of tumor mutational burden in pts with NSCLC
Zhang et al. 2020c Future Oncology 16: 469-481
Review
Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update
Hanna et al. 2020 JCO 38: 1608–1632
Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2022.2
Owen et al. 2023a J Clin Oncol 41: e10-e20

AI Chat

7/1/2026

Chat with our artificial intelligence: